| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K: Regulation FD Disclosure; Other Events
In myositis, 5/6 (83%) patients treated at 4 billion cells per dose with at least three months of follow-up achieved moderate or major responses, as measured by the Total Improvement Score (TIS) in the Ntrust-2 study of NKX019, an invest... |
| 06 Nov 2026 |
8-K: Regulation FD Disclosure
SOUTH SAN FRANCISCO, Calif., November 6, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced ... |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Initial clinical data for NKX019 in idiopathic inflammatory myopathy (myositis) and systemic sclerosis (scleroderma) to be presented at ACR Convergence 2026 |
| 10 Aug 2026 | 10-Q |
| 10 Aug 2026 |
8-K: Results of Operations and Financial Condition
Enrollment continues across all indications in Ntrust-1 and Ntrust-2 at the 4 billion cell dose level (12 billion cells in 3-dose cycle) |
| 22 Jun 2026 |
Form 4: Hastings Paul J, Director
Sold 1,776 shares ($4.81K) |
| 11 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
The 2026 annual meeting of stockholders (the "Annual Meeting") of Nkarta, Inc. (the "Company") was held on June 10, 2026. The results of the voting at the Annual Meeting are set forth below. |
| 11 Jun 2026 |
Form 4: Ra Capital MANAGEMENT, L.p., Director and 4 others
Granted 37,000 Stock Option (right to buy) |
| 11 Jun 2026 |
Form 4: Behbahani Ali, Director
Granted 37,000 Stock Option (right to buy) |
| 11 Jun 2026 |
Form 4: George Simeon, Director
Granted 37,000 Stock Option (right to buy) |
| 11 Jun 2026 |
Form 4: Vratsanos George, Director
Granted 37,000 Stock Option (right to buy) |
| 11 Jun 2026 |
Form 4: Scheiner Zachary, Director
Granted 37,000 Stock Option (right to buy) |
| 11 Jun 2026 |
Form 4: Patterson Leone D, Director
Granted 37,000 Stock Option (right to buy) |
| 11 Jun 2026 |
Form 4: Dybbs Michael, Director
Granted 37,000 Stock Option (right to buy) |
| 11 Jun 2026 |
Form 4: Thedinga Angela, Director
Granted 37,000 Stock Option (right to buy) |
| 19 May 2026 | SCHEDULE 13D/A |
| 12 May 2026 | 10-Q |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition
Enrollment ongoing at 4 billion cell dose level (12 billion cells in 3-dose cycle) across all indications in Ntrust-1 and Ntrust-2 |
| 23 Apr 2026 | ARS |
Loading...